HENNIGSDORF and BERLIN, Germany, October 31 /PRNewswire/ -- Revotar Biopharmaceuticals AG., today announced first positive results from an investigator driven open labelled Phase IIa pilot study in 14 patients with stable COPD stage 0 to II (GOLD criteria) inhaling 70 mg of Bimosiamose twice a day. The study was conducted at the Charité - Medical School Charité Berlin, Prof. Witt and the Respiratory Institute Wiesbaden, Dr. Beeh. The results were presented during the recent European Respiratory Society Meeting in Stockholm in September.
"Despite of the short treatment period we were surprised to see that analysis of induced sputum prior to and after Bimosiamose treatment of 9 days showed that both relative and absolute lymphocytes count decreased significantly. In addition, sputum IL-8 was significantly decreased. The latter is supposed to correlate with the severity of the disease," commented Prof. Dr. Meyer-Sabellek, clinical advisor to Revotar and previously SVP Research&Development at AstraZeneca, Germany. "Inhalation of Bimosiamose twice daily for up to 9 days was well tolerated and safe in patients. This targeted therapy provides the potential to prevent the further progression of inflammatory components in COPD and should be evaluated further in larger clinical trials," added Prof. Dr. Witt from the Charité and the Principal Investigator of the study.
Chronic Obstructive Pulmonary Disease (COPD) comprises many serious conditions affecting the lung. More than 30 million people are living with COPD worldwide. COPD is the fourth leading cause of death and is responsible for more than 120,000 deaths a year in the US and Western Europe alone. The disease costs the US healthcare system US$40 billion per year.
About Revotar Biopharmaceutical AG
Revotar develops innovative anti-inflammatory drugs for inflammatory indications such as psoriasis, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Bimosiamose has already passed several clinical Phase I and Phase IIa trials in asthma and psoriasis with a good safety and efficacy profile in over 140 human beings. In summer 2006 Revotar announced the signing of a Start-Up Development Agreement with a US Pharma company for the further development of Bimosiamose in one major disease area. Revotar will present during the BioEurope conference in Hamburg on November 14, 2007.
Contact Address: Stephan Tarlach Executive Board Revotar Biopharmaceuticals AG Neuendorfstr. 24a D-16761 Hennigsdorf phone: +49-3302-2025040 fax: +49-3302-2025030 e-mail: firstname.lastname@example.org
Contact Address: Stephan Tarlach, Executive Board, Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, D-16761 Hennigsdorf, phone: +49-3302-2025-010, fax: +49-3302-2025-030, e-mail: email@example.com